View Archive »
About The Cover
In vivo effect of fasting cycles in combination with chemotherapy on tumor glucose consumption and cancer growth. Patlak-map of a mouse, see Bianchi et al.
|
|
Table of Contents
Editorial
|
| p53induced autophagy and senescence |
|
https://doi.org/10.18632/oncotarget.4170
|
| 11723-11724 |
Reviews
|
| The emerging role of CaMKII in cancer |
|
https://doi.org/10.18632/oncotarget.3955
|
| 11725-11734 |
|
| Initiation and termination of DNA replication during S phase in relation to cyclins D1 E and A p21WAF1 Cdt1 and the p12 subunit of DNA polymerase δ revealed in individual cells by cytometry |
|
https://doi.org/10.18632/oncotarget.4149
|
| 11735-11750 |
Priority Research Papers
|
| Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition |
|
https://doi.org/10.18632/oncotarget.3996
|
| 11751-11767 |
|
| HIF1α and TAZ serve as reciprocal coactivators in human breast cancer cells |
|
https://doi.org/10.18632/oncotarget.4190
|
| 11768-11778 |
|
| CSN6 deregulation impairs genome integrity in a COP1dependent pathway |
|
https://doi.org/10.18632/oncotarget.3151
|
| 11779-11793 |
|
| ERp19 contributes to tumorigenicity in human gastric cancer by promoting cell growth migration and invasion |
|
https://doi.org/10.18632/oncotarget.3649
|
| 11794-11805 |
|
| Fasting induces antiWarburg effect that increases respiration but reduces ATPsynthesis to promote apoptosis in colon cancer models |
|
https://doi.org/10.18632/oncotarget.3688
|
| 11806-11819 |
|
| Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition |
|
https://doi.org/10.18632/oncotarget.3689
|
| 11820-11832 |
|
| AMPactivated protein kinase is dispensable for maintaining ATP levels and for survival following inhibition of glycolysis but promotes tumour engraftment of Rastransformed fibroblasts |
|
https://doi.org/10.18632/oncotarget.3738
|
| 11833-11847 |
|
| RAB7 counteracts PI3Kdriven macropinocytosis activated at early stages of melanoma development |
|
https://doi.org/10.18632/oncotarget.4055
|
| 11848-11862 |
|
| cJun Nterminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression |
|
https://doi.org/10.18632/oncotarget.3787
|
| 11863-11881 |
|
| Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy |
|
https://doi.org/10.18632/oncotarget.3592
|
| 11882-11893 |
|
| Metaanalysis of organspecific differences in the structure of the immune infiltrate in major malignancies |
|
https://doi.org/10.18632/oncotarget.4180
|
| 11894-11909 |
|
| Cripto1 as a novel therapeutic target for triple negative breast cancer |
|
https://doi.org/10.18632/oncotarget.4182
|
| 11910-11929 |
Research Papers: Pathology
|
| Smad7 protects against chronic aristolochic acid nephropathy in mice |
|
https://doi.org/10.18632/oncotarget.3718
|
| 11930-11944 |
|
| Aquaporin 1 and 5 expression decreases during human intervertebral disc degeneration: novel HIF1mediated regulation of aquaporins in NP cells |
|
https://doi.org/10.18632/oncotarget.3631
|
| 11945-11958 |
Research Papers: Gerotarget (Focus on Aging)
|
| Systemic attenuation of the TGFβ pathway by a single drug simultaneously rejuvenates hippocampal neurogenesis and myogenesis in the same old mammal |
|
https://doi.org/10.18632/oncotarget.3851
|
| 11959-11978 |
|
| Combined effects of aging and inflammation on reninangiotensin system mediate mitochondrial dysfunction and phenotypic changes in cardiomyopathies |
|
https://doi.org/10.18632/oncotarget.3979
|
| 11979-11993 |
Research Papers
|
| CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities |
|
https://doi.org/10.18632/oncotarget.2740
|
| 11994-12008 |
|
| Filamin A phosphorylation by Akt promotes cell migration in response to arsenic |
|
https://doi.org/10.18632/oncotarget.3617
|
| 12009-12019 |
|
| Therapeutic targeting of pololike kinase 1 using RNAinterfering nanoparticles iNOPs for the treatment of nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.2664
|
| 12020-12034 |
|
| Epidermal growth factor receptor mutation mediates crossresistance to panitumumab and cetuximab in gastrointestinal cancer |
|
https://doi.org/10.18632/oncotarget.3574
|
| 12035-12047 |
|
| CXCL12induced VLA4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21 |
|
https://doi.org/10.18632/oncotarget.3660
|
| 12048-12060 |
|
| TIMP1 activated carcinomaassociated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.3616
|
| 12061-12079 |
|
| Differential expression of cell cycle regulators in CDK5dependent medullary thyroid carcinoma tumorigenesis |
|
https://doi.org/10.18632/oncotarget.3813
|
| 12080-12093 |
|
| From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity |
|
https://doi.org/10.18632/oncotarget.3297
|
| 12094-12109 |
|
| Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer |
|
https://doi.org/10.18632/oncotarget.3661
|
| 12110-12127 |
|
| Discovery of a small molecule targeting SETPP2A interaction to overcome BCRABLT315I mutation of chronic myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.3665
|
| 12128-12140 |
|
| The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma |
|
https://doi.org/10.18632/oncotarget.3716
|
| 12141-12155 |
|
| Tudor staphylococcal nuclease drives chemoresistance of nonsmall cell lung carcinoma cells by regulating S100A11 |
|
https://doi.org/10.18632/oncotarget.3495
|
| 12156-12173 |
|
| Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth |
|
https://doi.org/10.18632/oncotarget.3650
|
| 12174-12187 |
|
| miR20b is upregulated in brain metastases from primary breast cancers |
|
https://doi.org/10.18632/oncotarget.3664
|
| 12188-12195 |
|
| Hepatitis B virus X protein induces expression of alphafetoprotein and activates PI3K/mTOR signaling pathway in liver cells |
|
https://doi.org/10.18632/oncotarget.2906
|
| 12196-12208 |
|
| FKBPL: a marker of good prognosis in breast cancer |
|
https://doi.org/10.18632/oncotarget.3528
|
| 12209-12223 |
|
| Identification of a novel TGFβmiR122fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis |
|
https://doi.org/10.18632/oncotarget.3652
|
| 12224-12233 |
|
| Multiplatform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets |
|
https://doi.org/10.18632/oncotarget.3498
|
| 12234-12247 |
|
| Loss of the Nterminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis |
|
https://doi.org/10.18632/oncotarget.3653
|
| 12248-12263 |
|
| Estrogen receptor ER was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer |
|
https://doi.org/10.18632/oncotarget.3654
|
| 12264-12278 |
|
| Oncometabolic mutation IDH1 R132H confers a metforminhypersensitive phenotype |
|
https://doi.org/10.18632/oncotarget.3733
|
| 12279-12296 |
|
| Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy |
|
https://doi.org/10.18632/oncotarget.3655
|
| 12297-12309 |
|
| Celecoxib increases EGF signaling in colon tumor associated fibroblasts modulating EGFR expression and degradation |
|
https://doi.org/10.18632/oncotarget.3678
|
| 12310-12325 |
|
| Infiltrated preadipocytes increase prostate cancer metastasis via modulation of the miR301a/androgen receptor AR/TGFβ1/Smad/MMP9 signals |
|
https://doi.org/10.18632/oncotarget.3619
|
| 12326-12339 |
|
| Sorafenib and DE605 a novel cMet inhibitor synergistically suppress hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.3656
|
| 12340-12356 |
|
| PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression |
|
https://doi.org/10.18632/oncotarget.3657
|
| 12357-12368 |
|
| Ex vivo generation of myeloidderived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer |
|
https://doi.org/10.18632/oncotarget.3682
|
| 12369-12382 |
|
| Loss of Wave1 gene defines a subtype of lethal prostate cancer |
|
https://doi.org/10.18632/oncotarget.3564
|
| 12383-12391 |
|
| TOPK is highly expressed in circulating tumor cells enabling metastasis of prostate cancer |
|
https://doi.org/10.18632/oncotarget.3630
|
| 12392-12404 |
|
| NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/βcatenin pathway and Bcl2 expression |
|
https://doi.org/10.18632/oncotarget.3618
|
| 12405-12420 |
|
| SRC family kinase SFK inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinasemediated differentiation |
|
https://doi.org/10.18632/oncotarget.3043
|
| 12421-12435 |
|
| Photochemical activation of MH3B1/rGel: a HER2targeted treatment approach for ovarian cancer |
|
https://doi.org/10.18632/oncotarget.3814
|
| 12436-12451 |
|
| SEL1L SNP rs12435998 a predictor of glioblastoma survival and response to radiochemotherapy |
|
https://doi.org/10.18632/oncotarget.3611
|
| 12452-12467 |
|
| Targeting the inhibitory receptor CTLA4 on T cells increased abscopal effects in murine mesothelioma model |
|
https://doi.org/10.18632/oncotarget.3487
|
| 12468-12480 |
|
| Induction of cCbl contributes to anticancer effects of HDAC inhibitor in lung cancer |
|
https://doi.org/10.18632/oncotarget.3489
|
| 12481-12492 |
|
| Combining TGFβ1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPIIL21 vaccine |
|
https://doi.org/10.18632/oncotarget.3722
|
| 12493-12504 |
|
| Inhibition of mutant IDH1 decreases D2HG levels without affecting tumorigenic properties of chondrosarcoma cell lines |
|
https://doi.org/10.18632/oncotarget.3723
|
| 12505-12519 |
|
| Biological and clinical effects of abiraterone on antiresorptive and anabolic activity in bone microenvironment |
|
https://doi.org/10.18632/oncotarget.3724
|
| 12520-12528 |
|
| Elevated OGlcNAcylation promotes colonic inflammation and tumorigenesis by modulating NFκB signaling |
|
https://doi.org/10.18632/oncotarget.3725
|
| 12529-12542 |
|
| miRNAtarget network reveals miR124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1 |
|
https://doi.org/10.18632/oncotarget.3815
|
| 12543-12557 |
|
| Tumor suppressive microRNA137 negatively regulates Musashi1 and colorectal cancer progression |
|
https://doi.org/10.18632/oncotarget.3726
|
| 12558-12573 |
|
| 5Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair |
|
https://doi.org/10.18632/oncotarget.3728
|
| 12574-12586 |
|
| Mycdependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer |
|
https://doi.org/10.18632/oncotarget.3494
|
| 12587-12602 |
|
| Quercetininduced apoptosis prevents EBV infection |
|
https://doi.org/10.18632/oncotarget.3687
|
| 12603-12624 |
|
| MAP17 PDZKIP1 as a novel prognostic biomarker for laryngeal cancer |
|
https://doi.org/10.18632/oncotarget.3470
|
| 12625-12636 |
|
| A STAT3NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations |
|
https://doi.org/10.18632/oncotarget.3703
|
| 12637-12653 |
|
| High USP22 expression indicates poor prognosis in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.3705
|
| 12654-12667 |
|
| Maritoclax and dinaciclib inhibit MCL1 activity and induce apoptosis in both a MCL1dependent and independent manner |
|
https://doi.org/10.18632/oncotarget.3706
|
| 12668-12681 |
|
| Organspecific adaptive signaling pathway activation in metastatic breast cancer cells |
|
https://doi.org/10.18632/oncotarget.3707
|
| 12682-12696 |
|
| FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC |
|
https://doi.org/10.18632/oncotarget.3708
|
| 12697-12709 |
|
| Genomic analysis of xCTmediated regulatory network: identification of novel targets against AIDSassociated lymphoma |
|
https://doi.org/10.18632/oncotarget.3710
|
| 12710-12722 |
|
| JARID1B promotes metastasis and epithelialmesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells |
|
https://doi.org/10.18632/oncotarget.3713
|
| 12723-12739 |
|
| A standardized autopsy procurement allows for the comprehensive study of DIPG biology |
|
https://doi.org/10.18632/oncotarget.3374
|
| 12740-12747 |
|
| Metformin potentiates rapamycin and cisplatin in gastric cancer in mice |
|
https://doi.org/10.18632/oncotarget.3327
|
| 12748-12762 |
Clinical Research Papers
|
| The prognostic value of the stemlike group in colorectal cancer using a panel of immunohistochemistry markers |
|
https://doi.org/10.18632/oncotarget.3497
|
| 12763-12773 |
|
| Differences in breast cancer characteristics and outcomes between Caucasian and Chinese women in the US |
|
https://doi.org/10.18632/oncotarget.3666
|
| 12774-12782 |
|
| Molecular heterogeneity assessment by nextgeneration sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.3727
|
| 12783-12795 |
|
| Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPYâ€phase 12 trial |
|
https://doi.org/10.18632/oncotarget.3473
|
| 12796-12808 |
|
| Actionable mutations in plasma cellfree DNA in patients with advanced cancers referred for experimental targeted therapies |
|
https://doi.org/10.18632/oncotarget.3373
|
| 12809-12821 |
|
| HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy |
|
https://doi.org/10.18632/oncotarget.3431
|
| 12822-12834 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
